MBX Biosciences, Inc.

MBX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $54.1M $45.2M $75.3M $223.1M $39.8M $29.9M $49.4M $132.9M
Accounts Receivable
Inventory
Total Current Assets $427.9M $448.5M $381.5M $397.5M $229.2M $244.3M $267.3M $281.2M
Property, Plant & Equipment $4.7M $3.1M $2.7M $2.0M $1.7M $1.5M $1.1M $1.0M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $435.9M $452.7M $385.1M $400.1M $231.5M $245.9M $268.5M $282.4M
Liabilities
Accounts Payable $4.4M $7.0M $3.0M $3.8M $5.8M $4.2M $5.3M $5.0M
Total Current Liabilities $23.7M $14.6M $15.5M $12.1M $11.8M $10.5M $11.1M $10.9M
Long-Term Debt
Total Liabilities $26.4M $14.9M $15.9M $12.5M $12.3M $10.5M $11.1M $11.0M
Stockholders' Equity
Retained Earnings $-285.1M $-248.0M $-224.5M $-202.4M $-180.8M $-161.4M $-137.5M $-121.9M
Total Stockholders' Equity $409.5M $437.8M $369.2M $387.5M $219.2M $235.4M $257.4M $271.4M
← Newer Page 1 of 2 Older →